Treatments for the symptomatic relief of Alzheimer's disease are available but despite advances in our ability to treat persons with various forms of dementia, more effective treatments are needed. The cholinesterase inhibitors donepezil, rivastigmine, and galantamine have demonstrated efficacy in improving cognition and global status and to a lesser extent, behavioral abnormalities relative to...

BACKGROUND/AIMS The present study evaluated the differences in treatment outcomes and brain perfusion changes among 3 types of acetylcholinesterase inhibitors (AchEIs, i.e. donepezil, rivastigmine, and galantamine). METHODS This was a prospective, longitudinal, randomized, open-label, 3-arm (donepezil, rivastigmine, or galantamine), parallel-group, 12-month clinical trial carried out in 55 pa...

Cholinesterase inhibitors such as donepezil, galantamine and rivastigmine can slow the progression of Alzheimer’s disease and provide symptomatic relief but require daily administration (donepezil) or twice daily administration (galantamine and rivastigmine). These medications, of course, only have efficacy if actually taken on a regular basis. A clinical vignette is described here of a patient...

Alzheimer’s disease (AD) is the most common type of dementia in elderly population. With a growing aging population not only in the United States but also in the worldwide, AD constitutes an emergent public health problem. Over decades, the prevailing hypothesis was that neurodegeneration might result from one or two of the specific lesions that characterize AD, e.g., accumulation of amyloid pl...